Quick Answer
Amycretin is an experimental weight loss drug from Novo Nordisk (the same company that makes Ozempic and Wegovy). It targets two receptors — GLP-1 and amylin — and it comes as a daily pill, not an injection.
Early trial results are promising, but amycretin is in early clinical trials and is years away from being available. It is not FDA-approved.
How Amycretin Works
Amycretin targets two receptors:
- GLP-1 receptor: Reduces appetite and slows digestion (same as Ozempic, Wegovy, Mounjaro)
- Amylin receptor: Reduces appetite through a different pathway and helps control blood sugar after meals
Amylin is a hormone that your pancreas makes along with insulin. It helps you feel full and slows down how fast food leaves your stomach. People with type 2 diabetes often have low amylin levels.
By hitting both GLP-1 and amylin, amycretin suppresses appetite from two different angles. This dual approach is similar in concept to how Mounjaro/Zepbound target GLP-1 + GIP — but amycretin uses a different second target.
Why a Pill Matters
All currently approved GLP-1 medications are injections (weekly for most, daily for Saxenda). A pill would be a big deal for people who:
- Are afraid of needles
- Travel frequently and worry about refrigeration
- Prefer the convenience of a daily pill
- Want an option that doesn't require injection supplies
Rybelsus (oral semaglutide) already exists as a pill, but it has lower absorption and less weight loss than injected semaglutide. Amycretin may work differently.
Weight Loss Results So Far
Phase 1 data (12 weeks):
| Dose | Weight Loss (12 weeks) |
|---|---|
| Low dose | ~6% |
| Higher dose | ~13% |
For comparison:
- Ozempic: ~15% over 68 weeks
- Wegovy: ~15% over 68 weeks
- Zepbound: ~20% over 72 weeks
Important caveat: You can't directly compare 12 weeks of amycretin data to 68+ weeks of Ozempic data. The amycretin numbers will likely increase with longer treatment. But it's too early to say where they'll land.
Amycretin vs Ozempic: Key Differences
| Feature | Amycretin | Ozempic |
|---|---|---|
| Mechanism | GLP-1 + amylin | GLP-1 only |
| Form | Daily pill | Weekly injection |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA approved | No | Yes |
| Available | No | Yes |
| Best weight loss data | ~13% (12 weeks) | ~15% (68 weeks) |
| Dosing frequency | Daily | Weekly |
Potential Advantages of Amycretin
- It's a pill. No needles, no refrigeration concerns, no injection-site reactions.
- Dual mechanism. Targeting amylin alongside GLP-1 may produce better weight loss than GLP-1 alone.
- Same company as Ozempic. Novo Nordisk has deep experience with GLP-1 drugs.
Potential Disadvantages
- Daily dosing. Some people prefer weekly injections to daily pills.
- Less proven. Early trial data only. Long-term safety and effectiveness unknown.
- Years away. Not available until at least 2028-2029, possibly later.
When Could Amycretin Be Available?
Amycretin is in phase 1/early phase 2 trials as of 2026. This is very early in the drug development process.
Estimated timeline:
- Phase 2 trials: 2026-2027
- Phase 3 trials: 2027-2029
- FDA submission (if successful): 2029 or later
- Earliest possible approval: 2029-2030
This is an optimistic estimate. Most drugs that enter phase 1 never make it to market. Amycretin could fail, be delayed, or turn out to be less effective than expected.
Other Pipeline Drugs to Watch
Amycretin isn't the only experimental GLP-1 drug. Also in development:
- Cagrisema (Novo Nordisk) — GLP-1 + amylin, in phase 3. See our cagrisema guide.
- Retatrutide (Eli Lilly) — GLP-1 + GIP + glucagon triple agonist, in phase 3. See our retatrutide guide.
- Survodutide (Boehringer Ingelheim) — GLP-1 + glucagon, in phase 3. See our survodutide guide.
Of these, retatrutide and cagrisema are further along in development than amycretin.
Should You Wait?
No. If you need help with weight loss now, the medications available today work well. Ozempic, Wegovy, Mounjaro, and Zepbound are all proven options.
Amycretin is years away from approval and there's no guarantee it will be better than what's already available. The pill format is appealing, but you shouldn't delay treatment for a drug that might not even reach the market.
Bottom Line
Amycretin is an interesting pipeline drug because it targets a new combination (GLP-1 + amylin) and comes as a pill. Early data looks good, but it's very early. It won't be available for years.
If you're choosing a GLP-1 medication today, focus on what's available now. Keep amycretin on your radar as a future option if it gets approved.
This article is for informational purposes only and does not constitute medical advice. Amycretin is not FDA-approved. Always talk to your healthcare provider before starting any medication.